Health-related quality of life in I-125 prostate brachytherapy patients treated with and without volume-reducing hormone therapy: Results of a short-term prospective study

Journal of Endourology

Volumn 23, Issue 1, 2009, Pages 153-159

  Mols, Floortje ^a,b   Stijns, Pascal ^c   Dankaart, Bram ^a   Houterman, Saskia ^b,d   Vingerhoets, Ad ^a   Hendrikx, Ad ^c  

^a TILBURG UNIVERSITY   (Netherlands)

^b The Netherlands   (Netherlands)

^c CATHARINA HOSPITAL   (Netherlands)

^d MÁXIMA MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; IODINE 125;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; HEALTH STATUS; HORMONAL THERAPY; HUMAN; IMPLANTATION; INSOMNIA; INTESTINE FUNCTION; MAJOR CLINICAL STUDY; MALE; PAIN; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SEXUAL FUNCTION; SOCIAL STATUS; TREATMENT OUTCOME;

ADULT; AGED; ANDROGENS; BRACHYTHERAPY; DEMOGRAPHY; HEALTH; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; TIME FACTORS;

EID: 59349093516     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2008.0089     Document Type: Article

References (27)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37(suppl 8):S4-S66.
2. Signaleringscommissie-Kanker, Kanker in Nederland. Trends, prognoses en implicaties voor zorgvraag. [Cancer in the Netherlands. Trends, prognosis and implications for health care.]. Amsterdam: KWF Kankerbestrijding, 2004.
3. Clark JA, Inui TS Silliman RA, Bokhour BG, Krasnow, SH, Robinson RA, Spaulding M, Talcott JA. Patients' perceptions of quality of life after treatment for early prostate cancer. J Clin Oncol 2003;21: 3777-3784.
4. Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE, Litwin MS, Nyquist L, Sanda MG. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 2002;20:557-566.
5. Lubeck DP, Grossfeld GD, Carroll PR. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. Urology 2001;58(suppl 1):94-100.
6. Miller DC, Sanda MG, Dunn RL, Montie JE, Pimentel H, Sandler HM, McLaughlin WP, Wei JT. Long-term outcomes among localized prostate cancer survivors: Health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 2005;23:2772-2780.
7. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Murray B, Zeroski D, Lief JH. Dysuria after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003;55:979-985.
8. Cesaretti JA, Stone NN, Stock RG. Urinary symptom flare following I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003;56:1085-1092.
9. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH. Long-term urinary quality of life after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003;56:454-461.
10. Potosky AL, Reeve BB, Clegg LX, Hoffman RM, Stephenson RA, Albertsen PC, Gilliland FD, Stanford JL. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 2002;94:430-437.
11. Basaria S, Lieb J II, Tang QAM, DeWeese T, Carducci M, Eisenberger M, Dobs AS. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002;56:779-786.
12. Pinkawa M, Fischedick K, Gagel B, Piroth MD, Borchers H, Jakse G, Ebie MJ. Association of neoadjuvant hormonal therapy with adverse health-related quality of life after permanent iodine-125 brachytherapy for localized prostate cancer. Urology 2006;68:104-109.
13. Lee LN, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 2002;52:444-452.
14. UICC. TNM Atlas: Illustrated Guide to the TNM/pTNM Classification of Malignant Tumors. Berlin: SpringerVerlag, 1992, pp 141-144.
15. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
16. Borghede G, Sullivan M. Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy. Development of a prostate cancer-specific module supplementing the EORTC QLQ-C30. Qual Life Res 1996;5:212-222.
17. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care 2003;41:582-592.
18. Sanda MG, Dunn RL, Sandler HM, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250-1261.
19. Van Gellekom MP, Moerland MA, Van Vulpen M, Wijrdeman HK, Battermann JJ. Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry. Int J Radiat Oncol Biol Phys 2005;63:772-780.
20. Egawa S, Shimura S, Irie A, Kitano M, Nishiguchi I, Kuwao S, Hayakawa K, Baba S. Toxicity and health-related quality of life during and after high dose rate brachytherapy followed by external beam radiotherapy for prostate cancer. Jpn J Clin Oncol 2001;31:541-547.
21. Wahlgren T, Brandberg Y, Häggarth L, Hellström M, Nilsson S. Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)ir brachytherapy: A prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25. Int J Radiat Oncol Biol Phys 2004;60:51-59.
22. Potters L, Torre T, Fearn PA, Leibel SA, Kattan MW. Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2001;50:1235-1242.
23. Merrick GS, Butler WM, Wallner KE, Murray BC, Allen Z, Galbreath RW. Influence of hormonal therapy on late rectal function after permanent prostate brachytherapy with or without supplemental external beam radiotherapy. Int J Radiat Oncol Biol Phys 2004;58:68-74.
24. Crook J, McLean M, Catton C, Yeung I, Tsihlias J, Pintilie M. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 2002;52:453-460.
25. Mols F, van de Poll-Franse LV, Vingerhoets AJ, Hendrikx A, Aaronson NK, Houterman S, Coebergh JW, Essink-Bot ML. Long-term quality of life among Dutch prostate cancer survivors: Results of a population-based study. Cancer 2006;107:2186-2196.
26. Mols F, Vingerhoets AJ, Coebergh JW, Vreugdenhil G, Aaronson NK, Lybeert ML, van de Poll-Franse LV. Better quality of life among 10-15 year survivors of Hodgkin's lymphoma compared to 5-9 year survivors: A population-based study. Eur J Cancer 2006;42:2794-2801.
27. Mols F, Aaronson NK, Vingerhoets AJ, Coebergh JW, Vreugdenhil G, Lybeert ML, van de Poll-Franse LV. Quality of life among long-term non-Hodgkin lymphoma survivors: A population-based study. Cancer 2007;109:1659-1667.